Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Clinical trial NCT06083844 · RECRUITING
Trial details
- NCT number
- NCT06083844
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-12
- Primary completion
- 2027-09-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.